Effects on abdominal symptoms of guanylate cyclase C-receptor agonist

Effects on abdominal symptoms of guanylate cyclase C-receptor agonist - Effects on abdominal symptoms of Linaclotide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028245

Enrollment

Registered

2017-07-14

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome

Interventions

administration of Linaclotide for 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients adepted for Linaclotide

Exclusion criteria

Exclusion criteria: 1. Patients who were diagnosed or suspected mechanical gastrointestinal obstruction 2. Patients with history of hypersensitivity to Linaclotide 3. Pregnant women or lactating women or patients who may have pregnancy 4. Cases judged inappropriate by the attending physician

Design outcomes

Primary

Measure	Time frame
Changes in subjective symptoms 2 weeks after satrting administration	—

Countries

Japan

Contacts

Public ContactManabe Noriaki

Kawasaki Medical School Division of Endoscopy and Ultrasonography

cda40950@hkg.odn.ne.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026